Contact this trialFirst, we need to learn more about you.
SGLT2 Inhibitor
SGLT2 Inhibitor for Kidney Transplant Recipients with Diabetes
Recruiting1 awardPhase 3
Toronto, Ontario
This trial will compare the SGLT2 inhibitor dapagliflozin to placebo in 52 kidney transplant recipients with diabetes. The primary outcome is to determine if dapagliflozin is superior to placebo in reduction of blood pressure in KTR.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.